Sarepta Therapeutics Inc (NASDAQ:SRPT) Receives $194.25 Consensus Price Target from Analysts

Sarepta Therapeutics Inc (NASDAQ:SRPT) has been given an average recommendation of “Buy” by the twenty-seven brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, two have issued a hold rating and twenty-three have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $194.79.

SRPT has been the subject of several recent research reports. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $206.00 to $200.00 and set an “overweight” rating for the company in a research note on Tuesday, August 4th. Raymond James initiated coverage on shares of Sarepta Therapeutics in a research report on Monday, August 24th. They issued an “outperform” rating and a $200.00 price objective on the stock. Bank of America dropped their price objective on shares of Sarepta Therapeutics from $190.00 to $189.00 and set a “buy” rating on the stock in a research note on Friday, August 21st. Robert W. Baird restated a “buy” rating and issued a $192.00 target price on shares of Sarepta Therapeutics in a research note on Monday, June 8th. Finally, Morgan Stanley boosted their price target on shares of Sarepta Therapeutics from $172.00 to $182.00 and gave the stock an “overweight” rating in a research note on Monday, August 10th.

NASDAQ SRPT traded up $1.15 on Wednesday, reaching $143.95. The stock had a trading volume of 793,790 shares, compared to its average volume of 873,711. The stock has a market cap of $11.30 billion, a P/E ratio of -20.51 and a beta of 1.84. Sarepta Therapeutics has a 12-month low of $72.05 and a 12-month high of $175.00. The business’s 50-day moving average price is $147.14 and its 200 day moving average price is $137.10. The company has a debt-to-equity ratio of 0.67, a quick ratio of 6.42 and a current ratio of 6.93.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.73) by ($0.20). Sarepta Therapeutics had a negative net margin of 117.80% and a negative return on equity of 53.02%. The business had revenue of $137.36 million during the quarter, compared to analysts’ expectations of $112.36 million. On average, sell-side analysts predict that Sarepta Therapeutics will post -7.28 earnings per share for the current year.

In other news, insider Joseph Bratica sold 1,125 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $155.00, for a total value of $174,375.00. Following the sale, the insider now directly owns 8,957 shares in the company, valued at $1,388,335. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David T. Howton sold 105,122 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $170.88, for a total transaction of $17,963,247.36. Following the transaction, the executive vice president now directly owns 33,151 shares of the company’s stock, valued at $5,664,842.88. The disclosure for this sale can be found here. Over the last three months, insiders sold 146,247 shares of company stock worth $24,482,622. 5.90% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amundi Pioneer Asset Management Inc. boosted its position in Sarepta Therapeutics by 32.8% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,611 shares of the biotechnology company’s stock worth $18,428,000 after acquiring an additional 38,194 shares during the last quarter. Envestnet Asset Management Inc. grew its position in shares of Sarepta Therapeutics by 5.9% in the first quarter. Envestnet Asset Management Inc. now owns 3,495 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 196 shares during the period. Steward Partners Investment Advisory LLC increased its stake in Sarepta Therapeutics by 46.1% in the first quarter. Steward Partners Investment Advisory LLC now owns 317 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 100 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its position in Sarepta Therapeutics by 5.6% during the first quarter. Public Employees Retirement Association of Colorado now owns 11,135 shares of the biotechnology company’s stock worth $1,089,000 after buying an additional 590 shares during the period. Finally, KBC Group NV boosted its stake in Sarepta Therapeutics by 46.8% in the 1st quarter. KBC Group NV now owns 7,985 shares of the biotechnology company’s stock worth $781,000 after buying an additional 2,544 shares during the last quarter. 92.70% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: What is the formula for the cash asset ratio?

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.